S.I. No. 582/2024 - Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2024 Skip to content Disclaimer Feedback Helpdesk Gaeilge Léim go dtí an t-ábhar Séanadh Aiseolas Deasc chabhrach English Gaeilge English Produced by the Office of the Attorney General Táirgthe ag Oifig an Ard-Aighne Home Legislation Acts of the Oireachtas Statutory Instruments Pre-1922 Legislation Constitution External Resources Bills (Houses of the Oireachtas) Iris Oifigiúil / Official Gazette Revised Acts (LRC) Classified List of Legislation (LRC) Translations (acts.
- ie)Translations (Houses of the Oireachtas) Government Publications for Sale EU Law (EUR-Lex) FAQ Disclaimer Feedback Helpdesk Search Baile Reachtaíocht Achtanna an Oireachtais Ionstraimí Reachtúla Reachtaíocht Réamh-1922 Bunreacht Acmhainní Seachtracha Billí (Tithe an Oireachtais) Iris Oifigiúil Achtanna Athbhreithnithe (CAD) (An Coimisiún um Athchóiriú an Dlí) Liosta Rangaithe Reachtaíochta Aistriúcháin (achtanna.
- ie)Aistriúcháin (Tithe an Oireachtais) Foilseacháin Rialtais ar Díol Dlí AE (EUR-Lex) CCanna (Ceisteanna Coitianta) Séanadh Aiseolas Deasc chabhrach Cuardach TitleTeideal Year(
- s)or rangeBliain nó blianta nó raon TypeCineál All Legislation Acts Statutory Instruments Advanced SearchCuardach Casta HomeBaile Statutory InstrumentsIonstraimí Reachtúla 2024 S.I. No. 582/2024 - Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2024 S.I. No. 582/2024 - Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2024 AmendmentsLeasuithe Download PDF Íoslódáil PDF Notice of the making of this Statutory Instrument was published in “Iris Oifigiúil” of 1st November, 2024. I, STEPHEN DONNELLY, in exercise of the powers conferred on me by section 32 (as amended by section 16 of the Irish Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make the following regulations: 1.
(1)These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2024.
(2)The collective citation “the Medicinal Products (Prescription and Control of Supply) Regulations 2003 to 2024” includes these Regulations.
- These Regulations shall come into operation on 31st October
- In these Regulations – “Principal Regulations” means the Medicinal Products (Prescription and Control of Supply) Regulations 2003 ( S.I. No. 540 of 2003 ); “Regulations of 2024” means the Medicinal Products (Prescription and Control of Supply) (No. 4) Regulations 2024 ( S.I. No. 458 of 2024 ). The Eighth Schedule (as amended by Regulation 7 of the 2024 Regulations) to the Principal Regulations is amended by inserting the following entry: “ Medicinal product Form and presentation of the product administered Route of administration Indication for which the medicinal product may be administered Dosage and conditions of administration Place of administration Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Comirnaty KP.2 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product. Comirnaty KP.2 10 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years. In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product. Comirnaty KP.23 micrograms/dose concentrate for dispersion COVID-19 mRNA Vaccine Concentrate for dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years. In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product. Nuvaxovid JN.1 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product. ”. The Twelfth Schedule (as amended by Regulation 8 of the 2024 Regulations) to the Principal Regulations is amended by inserting the following entry: “ Medicinal product Form and presentation of product administered Route of administration Indication for which the medicinal product may be administered Dosage and conditions of administration Column 1 Column 2 Column 3 Column 4 Column 5 Comirnaty KP.2 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Comirnaty KP.2 10 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years. In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Comirnaty KP.2 3 micrograms/dose concentrate for dispersion COVID-19 mRNA Vaccine Concentrate for dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years. In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Nuvaxovid JN.1 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. ”. GIVEN under my Official Seal, 30 October,
- STEPHEN DONNELLY, Minister for Health. EXPLANATORY NOTE (This note is not part of the Instrument and does not purport to be a legal interpretation.) These Regulations amend the Medicinal Products (Prescription and Control of Supply) Regulations
- The purpose of these Regulations is to update the schedules of medicinal products which may be supplied and administered pursuant to Regulation 4B and Regulation 4F of the Medicinal Products (Prescription and Control of Supply) Regulations
- These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 5) Regulations
- Privacy Statement Accessibility European Legislation Identifier (PDF) Open Data License Ráiteas Príobháideachais Inrochtaineacht Aitheantóir Eorpach Reachtaíochta (ELI) Ceadúnas Sonraí Oscailte Liosta Fianán © Government of Ireland. Oireachtas Copyright Material is reproduced with the permission of the Houses of the Oireachtas © Rialtas na hÉireann. Atáirgtear ábhar faoi Chóipcheart le cead ó Thithe an Oireachtais